Brandes Investment Partners LP Has $4.35 Million Stock Holdings in Organon & Co. $OGN

Key Points

• Brandes Investment Partners LP boosted its Organon stake by 46.7% in Q4, buying 193,064 additional shares and bringing its holdings to 606,499 shares worth about $4.35 million.
• Insider buying was notable as SVP Lynette Holzbaur purchased 26,448 shares at $13.35 each, more than doubling her ownership in the company.
• Analyst sentiment remains cautious: several firms recently raised price targets or upgraded ratings, but the stock still carries an average "Reduce" rating with a consensus price target of $11.40.

Brandes Investment Partners LP increased its position in shares of Organon & Co. (NYSE:OGN - Free Report) by 46.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 606,499 shares of the company's stock after purchasing an additional 193,064 shares during the quarter. Brandes Investment Partners LP owned approximately 0.23% of Organon & Co. worth $4,349,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in OGN. Beddow Capital Management Inc. increased its position in Organon & Co. by 2.4% in the 4th quarter. Beddow Capital Management Inc. now owns 666,725 shares of the company's stock valued at $4,780,000 after acquiring an additional 15,935 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Organon & Co. by 20.1% during the fourth quarter. Franklin Resources Inc. now owns 497,882 shares of the company's stock worth $3,570,000 after buying an additional 83,294 shares during the last quarter. Invst LLC bought a new stake in shares of Organon & Co. during the fourth quarter worth approximately $85,000. State of Wyoming raised its stake in shares of Organon & Co. by 33.9% during the fourth quarter. State of Wyoming now owns 50,352 shares of the company's stock worth $361,000 after buying an additional 12,734 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Organon & Co. by 13.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,880,615 shares of the company's stock worth $13,484,000 after buying an additional 223,953 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

Insider Activity

In other news, SVP Lynette Holzbaur bought 26,448 shares of the business's stock in a transaction that occurred on Wednesday, May 6th. The shares were bought at an average cost of $13.35 per share, for a total transaction of $353,080.80. Following the acquisition, the senior vice president directly owned 52,851 shares in the company, valued at approximately $705,560.85. This trade represents a 100.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.62% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on OGN shares. Barclays lifted their price objective on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 24th. Weiss Ratings raised shares of Organon & Co. from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Friday, May 15th. Zacks Research raised shares of Organon & Co. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, April 14th. BNP Paribas Exane reissued a "neutral" rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Finally, Piper Sandler raised shares of Organon & Co. from an "underweight" rating to a "neutral" rating and lifted their price objective for the stock from $5.00 to $14.00 in a research note on Tuesday, April 28th. Five analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Reduce" and an average price target of $11.40.

Organon & Co. Trading Down 0.2%

Shares of Organon & Co. stock opened at $13.38 on Thursday. The firm has a 50-day moving average of $11.32 and a 200-day moving average of $8.81. The stock has a market cap of $3.51 billion, a PE ratio of 14.38, a PEG ratio of 1.24 and a beta of 1.55. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.48. The company has a debt-to-equity ratio of 9.47, a quick ratio of 1.42 and a current ratio of 1.97.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing the consensus estimate of $0.83 by ($0.12). The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.49 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The company's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.02 EPS. As a group, sell-side analysts forecast that Organon & Co. will post 3.23 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Monday, May 11th will be issued a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, May 11th. Organon & Co.'s dividend payout ratio is presently 8.60%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.